Cognition Therapeutics, Inc. CGTX 深 沪
等待开盘 11-05 09:30:00 美东时间
0.6833
-0.016
-2.32%
华盛通- 最 高0.7292
- 今 开0.7199
- 成交量 42.11万股
- 最 低 0.68
- 昨 收 0.6995
- 总市值 6497.76万
- 52周最高 1.81
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 0.5501
- 委 比 95.38%
- 总股本 9509.37万
- 历史最高 13.80
- 量 比 1.13
- 振 幅 7.03%
- 历史最低 0.2223
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year.
今天 19:03
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 63.64 percent increase over losses of $(0.11) per share from the same period last year.
08-07 05:13
FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, today announced that it received written feedback from the U.S. Food and Drug Administration (FDA) following its recent meeting. ...
06-24 19:39
Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/56...
06-16 19:32
Cognition Therapeutics Announces Second Philanthropic Donation From A Participant In The Ongoing Expanded Access Program For People With Dementia With Lewy Bodies
The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach, FL.The open-label EAP
05-14 19:34
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
Cognition Therapeutics shares are trading lower. The company reported Q4 financial results.
Cognition Therapeutics shares are trading lower. The company reported Q4 financ...
03-27 23:53
Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 94.12 percent increase over losses of $(0.17) per share
03-26 19:32
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Cognition Therapeutics Presents Analysis From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AD/PD 2026 Alzheimer's & Parkinson's Diseases Conference
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study
03-17 19:35
